A mother and her seven-year-old daughter from Aylesbury have successfully completed treatment which will help to reduce the severity of allergic reactions to peanuts.

Palforzia, which is the first-ever treatment for peanut allergies, helps to mitigate against severe allergic reactions, including anaphylaxis in the event of unintended exposure to peanuts.

READ MORE: 'Parked it in a hedge & legged it' - Vehicles seized following reports of anti-social behaviour

According to AllergyUK.org, peanut allergies impact around two percent (one in 50) of children in the UK, with infants who have eczema or egg allergies being more likely to have a reaction if they were to have any foods related to peanuts.

If not treated effectively, those who suffer a reaction could go into an anaphylactic shock, which could lead to severe brain damage or even death.

Aimmune Therapeutics, Inc, is the science company that got the groundbreaking treatment off the mark, with the European Commission approving the treatment today.

READ MORE: 'Exercise will be a massive help to your mental health' - PT on staying fit during the pandemic

Andrew Oxtoby, President and CEO of Aimmune Therapeutics said: “Today’s [January 18] approval is a historic moment for the millions of people living with potentially life-threatening peanut allergy, and we are proud to bring Palforzia to patients in the EU who, until now, have not had an approved therapeutic option.

“We are grateful for the efforts of the peanut allergy community who contributed to the development program.

“Now we turn our efforts toward working with health authorities to ensure access of this first-of-kind treatment for those children with peanut allergy for whom our product is appropriate as we prepare to launch in Germany and the UK in May 2021.”

READ MORE: Driver who 'nearly crashed into a police dog unit' was 'over four times the drink-drive limit'

George du Toit, who is a professor of Paediatric Allergy at Evelina London Children’s Hospital added: “Results from landmark Phase 3 clinical trials have shown more than half of patients treated with Palforzia were able to tolerate the equivalent of seven to eight peanut kernels after up to nine months of treatment.

“The announcement is a very important step and means that we are closer than ever before to being able to provide an approved treatment for patients with peanut allergy.”